Published in Ann Surg on September 01, 1982
Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas (SA02) | NCT00881595
Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol (2011) 2.39
Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg (1995) 2.28
Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg (1990) 2.17
The diagnosis and treatment of soft tissue sarcomas of the limbs. Dtsch Arztebl Int (2011) 1.70
Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg (1994) 1.65
High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg (2003) 1.63
Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann Surg Oncol (2010) 1.44
Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg (1992) 1.30
The role of radiation therapy in the management of sarcomas. Surg Clin North Am (2008) 1.25
Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res (2010) 1.19
Local recurrence of disease after unplanned excisions of high-grade soft tissue sarcomas. Clin Orthop Relat Res (2008) 1.11
Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis. Int J Radiat Oncol Biol Phys (2009) 1.09
Multidisciplinary management of soft tissue sarcoma. ScientificWorldJournal (2013) 1.08
Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys (2009) 1.08
Localized operable soft tissue sarcoma of the upper extremity. Presentation, management, and factors affecting local recurrence in 108 patients. Ann Surg (1987) 1.04
What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer (2014) 1.01
Application of IMRT in adjuvant treatment of soft tissue sarcomas of the thigh-Preliminary results. Rep Pract Oncol Radiother (2011) 0.97
Malignant tumours of the hand and wrist. Indian J Plast Surg (2011) 0.97
The enigma of myxofibrosarcoma of the extremity. Cancer (2011) 0.97
Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities. Radiat Oncol (2011) 0.97
Functional reconstruction of sarcoma defects utilising innervated free flaps. Sarcoma (2012) 0.93
Combined modality management of local and disseminated adult soft tissue sarcomas: a review of 257 cases seen over 10 years at the Christie Hospital & Holt Radium Institute, Manchester. Br J Cancer (1985) 0.91
Prognostic factors for survival in soft tissue sarcoma. Br J Cancer (1990) 0.89
Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma. Cancer (2011) 0.88
Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol (2012) 0.88
Primary pericardial sarcoma: a case report and a brief review. Cardiol Res Pract (2011) 0.87
Radiotherapy for soft tissue sarcoma of the proximal lower extremity. Sarcoma (2010) 0.86
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial. BMC Cancer (2014) 0.85
Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trials. Br J Cancer (1992) 0.85
Hyper-fractionated radiotherapy for soft tissue sarcoma: results of the second study of hyper-fractionated radiotherapy. Sarcoma (1999) 0.85
Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol (2007) 0.85
Concomitant upper extremity soft tissue sarcoma limb-sparing resection and functional reconstruction: assessment of outcomes and costs of surgery. Hand (N Y) (2014) 0.84
Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol (2007) 0.84
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr Treat Options Oncol (2007) 0.84
High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival. Int Orthop (2015) 0.84
Pattern of local recurrence after conservative surgery and radiotherapy for soft tissue sarcoma. Sarcoma (2001) 0.83
Managing soft tissue sarcomas in a developing country: are prognostic factors similar to those of developed world? World J Surg Oncol (2012) 0.83
Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br J Cancer (1999) 0.83
Quality of life following amputation or limb preservation in patients with lower extremity bone sarcoma. Front Oncol (2013) 0.83
Superficial soft tissue sarcomas of the extremities and trunk. World J Surg (2009) 0.83
High-grade undifferentiated small round cell sarcoma with t(4;19)(q35;q13.1) CIC-DUX4 fusion: emerging entities of soft tissue tumors with unique histopathologic features--a case report and literature review. Am J Case Rep (2015) 0.82
Functional outcome in limb-salvage surgery for soft tissue tumours of the foot and ankle. Sarcoma (1997) 0.82
Limb salvage for malignant bone and soft-tissue tumours of the shoulder girdle. Int Orthop (2003) 0.82
Management of extremity soft tissue sarcomas. Indian J Orthop (2011) 0.81
Sarcomas in the groin and inguinal canal--often missed and difficult to manage. Ann R Coll Surg Engl (2010) 0.81
Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system. Ann Surg Oncol (2008) 0.81
Radiation therapy for palliation of sarcoma metastases: a unique and uniform hypofractionation experience. Sarcoma (2010) 0.81
Factors Influencing Prognosis After Initial Inadequate Excision (IIE) for Soft Tissue Sarcoma. Sarcoma (2003) 0.80
Gemcitabine-mediated radiosensitization of human soft tissue sarcoma. Transl Oncol (2008) 0.80
High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy. BMC Cancer (2006) 0.80
Soft tissue sarcomas of the hand: functional reconstruction and outcome analysis. Hand (N Y) (2008) 0.80
Study of Preoperative Radiotherapy for Sarcomas of the Extremities with Intensity-Modulation, Image-Guidance and Small Safety-margins (PREMISS). BMC Cancer (2015) 0.80
Retroperitoneal sarcoma (RPS) high risk gross tumor volume boost (HR GTV boost) contour delineation agreement among NRG sarcoma radiation and surgical oncologists. Ann Surg Oncol (2015) 0.79
Modified vertical rectus abdominis musculocutaneous flap for limb salvage procedures in proximal lower limb musculoskeletal sarcomas. Sarcoma (2008) 0.79
Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma. Radiat Oncol J (2012) 0.79
Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma. Sarcoma (2015) 0.78
An analysis of factors related to the tail-like pattern of myxofibrosarcoma seen on MRI. Skeletal Radiol (2014) 0.78
Prevalence of malignant soft tissue tumors in extremities: an epidemiological study in syria. Arch Bone Jt Surg (2014) 0.78
A review of controversies in the management of soft tissue sarcomas. Indian J Surg (2012) 0.78
Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma (2006) 0.78
[Consensus diagnosis and therapy of soft tissue sarcoma]. Wien Klin Wochenschr (2011) 0.77
Treatment of Adult Soft Tissue Sarcomas: An Overview. Rare Cancers Ther (2015) 0.77
Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists. Int J Radiat Oncol Biol Phys (2015) 0.77
Microsurgical approach for unusual and unexpected malignant fibrous histiocytoma of the forearm: A case report. Mol Clin Oncol (2015) 0.77
Prognostic variables in patients with primary soft tissue sarcoma of the extremity and trunk treated with neoadjuvant radiotherapy or neoadjuvant sequential chemoradiotherapy. Radiat Oncol (2013) 0.77
The use of isolated limb infusion in limb threatening extremity sarcomas. Int J Hyperthermia (2012) 0.77
Wound complications in preoperatively irradiated soft-tissue sarcomas of the extremities. Int J Radiat Oncol Biol Phys (2012) 0.76
Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. Onco Targets Ther (2016) 0.76
Combining targeted agents with modern radiotherapy in soft tissue sarcomas. J Natl Cancer Inst (2014) 0.76
Principles in Management of Soft Tissue Sarcoma. Adv Surg (2015) 0.76
Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan. Eur J Nucl Med Mol Imaging (2014) 0.76
Isolated limb perfusion with biochemotherapy and oncolytic virotherapy combines with radiotherapy and surgery to overcome treatment resistance in an animal model of extremity soft tissue sarcoma. Int J Cancer (2016) 0.76
Evidence and clinical outcomes of adult soft tissue sarcomas of the extremities treated with adjuvant high-dose-rate brachytherapy - a literature review. J Contemp Brachytherapy (2014) 0.76
Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. Strahlenther Onkol (2013) 0.76
The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer Biol Med (2016) 0.76
Soft tissue sarcoma of the extremity. Ann R Coll Surg Engl (1996) 0.75
Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy. Hand (N Y) (2015) 0.75
Surgical Excision of Mycosis Fungoides Using Thumb-Sparing Reconstruction. Hand (N Y) (2016) 0.75
Soft tissue sarcoma of the extremities: pending questions on surgery and radiotherapy. Radiat Oncol (2016) 0.75
Imaging applications in multicatheter brachytherapy for soft tissue sarcomas. Cancer Imaging (2010) 0.75
Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma. Sarcoma (2015) 0.75
Intraoperative radiation therapy (IORT) in soft-tissue sarcoma. Radiat Oncol (2017) 0.75
CORR Insights(®): Use of Compressive Osteointegration Endoprostheses for Massive Bone Loss From Tumor and Failed Arthroplasty: A Viable Option in the Upper Extremity. Clin Orthop Relat Res (2017) 0.75
The Use of Radiation Therapy in Well-Differentiated Soft Tissue Sarcoma of the Extremities: An NCDB Review. Sarcoma (2015) 0.75
Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy. J Clin Oncol (2012) 0.75
Skin elasticity as a measure of radiation fibrosis: is it reproducible and does it correlate with patient and physician-reported measures? Technol Cancer Res Treat (2013) 0.75
Treatment of intimal sarcoma of peripheral veins. Int J Surg Case Rep (2017) 0.75
Plastic Surgery in the Multimodal Treatment Concept of Soft Tissue Sarcoma: Influence of Radiation, Chemotherapy, and Isolated Limb Perfusion on Plastic Surgery Techniques. Front Oncol (2015) 0.75
The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long-term community-based cancer center experience. Cancer Med (2017) 0.75
Functional Latissimus Dorsi Transfer for Upper-Extremity Reconstruction: A Case Report and Review of the Literature. Eplasty (2017) 0.75
Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience. Contemp Oncol (Pozn) (2017) 0.75
Primary high-grade soft-tissue sarcoma of the buttock: a rare but distinct clinical entity. Br J Radiol (2016) 0.75
Multimodality Management of Soft Tissue Tumors in the Extremity. Surg Clin North Am (2016) 0.75
Recent advances in the management of liposarcoma. F1000Res (2016) 0.75
Lymph node metastasis after a soft tissue sarcoma of the leg: a case report and a review of the literature. Case Rep Surg (2013) 0.75
Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. J Cancer Res Clin Oncol (2015) 0.75
Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma. J Contemp Brachytherapy (2017) 0.75
Intraoperative radiotherapy for extremity soft-tissue sarcomas: can long-term local control be achieved? Int J Clin Oncol (2017) 0.75
Fungation in soft tissue sarcomas is associated with poor survival. Int Orthop (2017) 0.75
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
The management of soft-tissue sarcomas of the extremities. J Bone Joint Surg Am (1976) 2.67
Surgical treatment of 297 soft tissue sarcomas of the lower extremity. Ann Surg (1975) 2.31
The problem of local recurrence after treatment of soft tissue sarcoma. Ann Surg (1968) 1.92
Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery (1982) 1.86
Chemotherapy of sarcoma. A comparison of three regimens. Lancet (1978) 1.75
Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer (1975) 1.73
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Soft tissue sarcomas. Ann Surg (1975) 1.49
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
Phase II evaluation of adriamycin in human neoplasia. Cancer (1973) 1.40
Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. Surgery (1978) 1.23
SOFT TISSUE SARCOMA. A REVIEW OF 200 CASES. Cancer (1963) 1.20
An experience with sarcomas of the soft tissues in adults. Surgery (1962) 1.14
Surgery and postoperative radiotherapy in the treatment of soft tissue sarcomas in adults. Am J Roentgenol Radium Ther Nucl Med (1975) 1.11
Radiation therapy technique in soft tissue sarcomas of the extremity--policies of treatment at the National Cancer Institute. Int J Radiat Oncol Biol Phys (1982) 1.06
Perspectives on the role of surgery and radiation therapy in the treatment of soft tissue sarcomas of the extremities. Semin Oncol (1981) 1.02
Effect of vincristine (NSC-67574) on malignant solid tumors in children. Cancer Chemother Rep (1968) 0.96
Sterile host yeasts (SHY): a eukaryotic system of biological containment for recombinant DNA experiments. Gene (1979) 19.39
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med (1991) 13.91
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst (1973) 10.64
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Attitudes and patterns of practice: a comparison of graduates of a residency program in family medicine and controls. J Fam Pract (1978) 5.09
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Consideration of the Possibility that the slow step in protein denaturation reactions is due to cis-trans isomerism of proline residues. Biochemistry (1975) 4.65
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Landscape ecology of algal symbionts creates variation in episodes of coral bleaching. Nature (1997) 4.53
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Sequence and expression of human estrogen receptor complementary DNA. Science (1986) 4.36
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Of scientific physicians and evidence-based medicine. Int J Radiat Oncol Biol Phys (2001) 3.94
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
Sentinel lymphadenectomy in breast cancer. J Clin Oncol (1997) 3.89
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
PicoGreen quantitation of DNA: effective evaluation of samples pre- or post-PCR. Nucleic Acids Res (1996) 3.74
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 3.60
Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis (1999) 3.48
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med (1995) 3.43
A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet (1998) 3.33
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Tissue microarray: a new technology for amplification of tissue resources. Cancer J (2001) 3.19
The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med (1997) 3.13
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
A database of vertebrate longevity records and their relation to other life-history traits. J Evol Biol (2009) 2.93
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
The lyase activity of the DNA repair protein beta-polymerase protects from DNA-damage-induced cytotoxicity. Nature (2000) 2.88
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med (1992) 2.79
Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr (1996) 2.77
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Assessing and planning home-based care for persons with AIDS. Health Policy Plan (1994) 2.71
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
Grieving abortion loss. AWHONN Lifelines (2002) 2.66
Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer (1976) 2.63
Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol (1994) 2.59
Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol (2001) 2.55
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol (1979) 2.36
Is routine episiotomy necessary? Br Med J (Clin Res Ed) (1984) 2.36
Passive immunotherapy of cancer in animals and man. Adv Cancer Res (1977) 2.32
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol (1992) 2.31
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol (1978) 2.29
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19
Human immune response to sand fly salivary gland antigens: a useful epidemiological marker? Am J Trop Med Hyg (2000) 2.18
A 42K outer-membrane protein is a component of the yeast mitochondrial protein import site. Nature (1989) 2.18
Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med (1992) 2.18
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. Radiology (1970) 2.16
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med (1991) 2.14
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13
Gamma globulin re-treatment in Kawasaki disease. J Pediatr (1993) 2.13
The fate of interleukin-2 after in vivo administration. J Immunol (1983) 2.13